Merck & Co., Inc.

NYSE:MRK

Drug Manufacturers - General

Healthcare
$137.78 -1.14%

-$1.32 today

Market cap
$339.66B
Beta
0.22
P/E (TTM)
31.6
EPS (TTM)
$3.61
Dividend yield
2.94%
52W Low $76.66High $125.14

Volume 9.69M

Average 11.85M

MRK EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Merck & Co., Inc.NYSE: MRK

EBITDA · Q2 FY2026 · quarter ended Jun 2026

EBITDA declines year over year

Q2 FY2026 EBITDA of $1.43B fell 77.8% year over year, behind the -44.4% change in trailing-twelve-month EBITDA. Over 3 fiscal years it compounded at +9.9% a year.

Context

  • EBITDA amounted to 43.5% of revenue in FY2025, up 3.5 pp from a year earlier.
  • EBITDA increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 18 analysts of $16.09B (-43.1%) for the fiscal year ending Dec 2026, a slowdown from the +9.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.43B+170.5% QoQ
Last fiscal yearDec 2025
$28.26B+9.9% YoY
LTMJun 2026
$13.93B-44.4% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-77.8%+9.8%+87.6 pp
1 year+9.9%-43.1%-53.0 pp
3-year CAGR+9.9%+11.7%+1.8 pp
5-year CAGR+6.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
28.26B USD
Year-over-year change
+9.9%
4-year CAGR
+12.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How MRK compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -44.4% is the 9th highest of 10, against a peer median of +10.8%.
  • EBITDA amounts to 21.0% of revenue for MRK, versus a peer median of 34.4%.
MRK Competitors
EBITDA for MRK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LLYEli Lilly and CompanyLTM Jun 2026$43.3B USD+103.7%+54.1%54.4%
JNJJohnson & JohnsonLTM Sep 2026$30.81B USD-22.1%+15.6%31.0%
ABBVAbbVie Inc.LTM Sep 2026$24.15B USD+88.7%-10.0%36.6%
NVSNovartis AGLTM Jun 2026$22.26B USD-2.0%+16.1%40.0%
AZNAstraZeneca PLCLTM Sep 2026$21.37B USD+18.6%+29.7%34.4%
AMGNAmgen Inc.LTM Jun 2026$17.62B USD+10.8%+11.6%46.2%
SNYSanofiLTM Jun 2026€14.77B EUR+15.5%-2.6%30.2%
MRKMerck & Co., Inc.LTM Jun 2026$13.93B USD-44.4%+9.9%21.0%
PFEPfizer Inc.LTM Jun 2026$13.49B USD-33.1%-25.8%21.2%
GILDGilead Sciences, Inc.LTM Jun 2026$1.33B USD-87.8%+15.3%4.4%
Peer median (excluding MRK) —+10.8%+15.3%34.4%

Competitors are the stored peer set for MRK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue48.7B59.28B60.12B64.17B64.93B
Cost of Revenue13.63B17.41B16.13B15.19B18.2B
Gross Profit35.08B41.87B43.99B48.98B46.73B
Gross Margin72.0%70.6%73.2%76.3%72.0%
Research & Development12.25B13.55B30.53B17.94B12.51B
Selling, General & Admin9.4B9.67B9.88B10.1B10.73B
Operating Expenses21.88B23.59B41.04B28.75B23.25B
Depreciation & Amortization3.21B3.91B3.87B4.5B5.84B
EBITDA17.9B21.32B6.91B25.71B28.26B
EBITDA Margin36.8%36.0%11.5%40.1%43.5%
Operating Income13.2B18.28B2.95B20.22B23.49B
Operating Margin27.1%30.8%4.9%31.5%36.2%
Interest Income36M157M365M415M343M
Interest Expense806M962M1.15B1.27B1.36B
Other Income / Expenses680M(1.84B)(1.07B)(285M)(2.42B)
Income Before Tax13.88B16.44B1.89B19.94B21.07B
Pre-Tax Margin28.5%27.7%3.1%31.1%32.4%
Income Tax Expense1.52B1.92B1.51B2.8B2.8B
Net Income13.05B14.52B365M17.12B18.25B
Net Margin26.8%24.5%0.6%26.7%28.1%
EPS (Basic)5.165.730.146.767.30
EPS (Diluted)5.145.710.146.747.28
Weighted Avg Shares2.53B2.53B2.55B2.53B2.5B
Weighted Avg Shares (Diluted)2.54B2.54B2.55B2.54B2.51B

Merck & Co., Inc.

NYSE:MRK

Intrinsic Alpha fair value

Locked

Current Price

$137.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.